Literature DB >> 19723399

Rifampicin serum levels in childhood tuberculosis.

S Thee1, A Detjen, U Wahn, K Magdorf.   

Abstract

BACKGROUND: Rifampicin (RMP) is an essential drug in paediatric anti-tuberculosis treatment. The current World Health Organization (WHO) guidelines recommend an oral dosage of 10 (8-12) mg per kg body weight.
OBJECTIVE: To present a study investigating RMP serum levels in children after oral medication of RMP alone and after combination treatment with ethambutol (EMB).
DESIGN: RMP serum levels in children of different age groups were determined after a single oral administration of 10 mg/kg RMP alone as well as after combination with 35 mg/kg EMB.
RESULTS: RMP serum levels were lower than those expected in adults receiving a similar oral dose. RMP serum levels in combination treatment were even lower than in monotherapy.
CONCLUSION: Currently recommended RMP dosages in childhood tuberculosis lead to serum levels lower than those recommended for adults, probably due to different pharmacokinetics and pharmacodynamics in children. In children, it appears to be more valid to calculate RMP dosage on the basis of body surface area rather than body weight, leading to higher dosages especially in younger children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723399

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  13 in total

1.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

Review 2.  A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children.

Authors:  Kyle John Wilby; Sara Shabana; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 3.  Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

4.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 5.  Pharmacokinetics of anti-tuberculosis drugs in children.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; Soumya Swaminathan
Journal:  Indian J Pediatr       Date:  2010-12-17       Impact factor: 1.967

6.  Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.

Authors:  Paolo Denti; Roeland E Wasmann; Annelies van Rie; Jana Winckler; Adrie Bekker; Helena Rabie; Anneke C Hesseling; Louvina E van der Laan; Carmen Gonzalez-Martinez; Heather J Zar; Gerry Davies; Lubbe Wiesner; Elin M Svensson; Helen M McIlleron
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

7.  Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.

Authors:  Wyatt J Roth; Candice B Kissinger; Robyn R McCain; Bruce R Cooper; Jeremy N Marchant-Forde; Rachel C Vreeman; Sophia Hannou; Gregory T Knipp
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

8.  Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Authors:  A Bekker; H S Schaaf; H R Draper; L van der Laan; S Murray; L Wiesner; P R Donald; H M McIlleron; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.

Authors:  Thomas Pouplin; Pham Nguyen Phuong; Pham Van Toi; Julie Nguyen Pouplin; Jeremy Farrar
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

10.  Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.

Authors:  Thomas Pouplin; Nguyen Duc Bang; Pham Van Toi; Pham Nguyen Phuong; Nguyen Huy Dung; Tran Ngoc Duong; Maxine Caws; Guy E Thwaites; Joel Tarning; Jeremy N Day
Journal:  BMC Infect Dis       Date:  2016-04-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.